Seasonal Influenza Vaccines Epidemiology Analysis and Forecast to 2032
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Seasonal Influenza Vaccines Report Overview
In the 7MM, there were 1,491,549 diagnosed incident cases of seasonal influenza vaccines in 2022. The diagnosed incident cases of seasonal influenza vaccines are expected to register a negative AGR of less than 1% during 2022-2032. Seasonal influenza (SI) is a contagious respiratory viral illness. There are four types of SI viruses: A, B, C, and D; however, only types A and B cause human disease of public health concern (WHO, 2023). Influenza transmission occurs when people with the flu cough, sneeze, or talk, thereby disseminating droplets. These droplets can land in the mouths or noses of people who then inhale them into the lungs (CDC, 2022).
Symptoms of influenza are headache, fever, cough, sore throat, and aching muscles and joints. The influenza virus tends to cause more severe disease in infants, elderly people, young children, and those with a weakened immune system (WHO, 2023).
Seasonal Influenza Vaccines Market Outlook, 2022-2032 (Diagnosed Incident Cases)
Buy the Full Report for More Insights into the Seasonal Influenza Vaccine Market Forecast
The Seasonal influenza vaccines market research report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for seasonal influenza vaccines in the seven major markets namely the US, France, Germany, Italy, Spain, UK, and Japan. The report also includes a 10-year epidemiology forecast for the diagnosed incident cases and diagnosed prevalent cases of seasonal influenza.
| Market Size (2022) | 1,491,549 Cases |
| AGR (2022-2032) | >(1)% |
| Forecast Period | 2023 – 2032 |
| Key Countries | · The US
· France · Germany · Spain · Italy · The UK · Japan |
| Key Sex Segments | · Men
· Women |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Seasonal Influenza Vaccines Market Segmentation by Country
The key countries across the 7 MM are the US, France, Germany, Spain, Italy, the UK, and Japan. The US had the highest number of diagnosed incident cases of seasonal influenza vaccines in 2022. However, the UK is expected to see the largest increase in diagnosed incident cases of lab-confirmed SI out of all the 7MM by 2032.
Seasonal Influenza Vaccines Market Analysis by Country, 2022 (%)
Buy the Full Report for More Country Insights into the Seasonal Influenza Vaccine Market
Seasonal Influenza Vaccines Market Segmentation by Sex
Based on sex, the seasonal influenza vaccine market can be segmented into men and women. In 2022, the number of diagnosed incident cases of seasonal influenza vaccines was higher in women than in men in the 7MM combined. In all markets, slightly more women were diagnosed than men except in the UK.
Seasonal Influenza Vaccines Market Analysis by Sex, 2022 (%)
Buy Full Report for More Sex Insights into the Seasonal Influenza Vaccines Market
Segments Covered in the Report
Seasonal Influenza Vaccines Market Country Outlook (Diagnosed Incident Cases, 2022-2032)
- The US
- France
- Germany
- Spain
- Italy
- The UK
- Japan
Seasonal Influenza Vaccines Market Sex Outlook (Diagnosed Incident Cases, 2022-2032)
- Men
- Women
Scope
- Seasonal Influenza (SI) vaccine Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of SI in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed incident cases of influenza-like illness (ILI), and lab-confirmed SI segmented by age (0–4 years, 5–17 years, 18–64 years, and ≥65 years) and sex. The report also includes a 10-year epidemiological forecast for the SI vaccinated population segmented by age (0–4 years, 5–17 years, 18–64 years, and ≥65 years). Seasonal Influenza (SI) vaccine Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of SI in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed incident cases of influenza-like illness (ILI), and lab-confirmed SI segmented by age (0–4 years, 5–17 years, 18–64 years, and ≥65 years) and sex. The report also includes a 10-year epidemiological forecast for the SI vaccinated population segmented by age (0–4 years, 5–17 years, 18–64 years, and ≥65 years).
- The Excel model accompanying this report includes lab-confirmed SI mortality, diagnosed incident cases of SI averted by vaccination, SI-related hospitalized cases, hospitalization averted by SI vaccination, and cases of ILI and lab-confirmed SI in third-trimester pregnant women.
Reasons to Buy
The seasonal influenza vaccines epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global seasonal influenza vaccines market.
- Quantify patient populations in the global seasonal influenza vaccine market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for seasonal influenza vaccine therapeutics in each of the markets covered.
Table of Contents
Table
Figures
Frequently asked questions
-
How many diagnosed incident cases of seasonal influenza vaccines were seen in the 7MM in 2022?
In 2022, there were 1,491,549 diagnosed incident cases of seasonal influenza vaccines in the 7MM.
-
What is the growth rate of the seasonal influenza vaccine market?
The diagnosed incident cases of seasonal influenza vaccines are expected to register a negative AGR of less than 1% during 2022-2032.
-
Which was the leading sex segment in the seasonal influenza vaccines market in 2022?
In 2022, the number of diagnosed prevalent cases of seasonal influenza vaccines was higher in women in the 7MM combined.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745


